Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

Next Previous
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Non-radiographic axial spondyloarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms BE MOBILE 1
  • Sponsors UCB Biopharma

    • Most Recent Events

    • 23 Sep 2024 According to an UCB media release, that the U.S. Food and Drug Administration (FDA) has approved BIMZELX for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS). The approvals are supported by data from the Phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
    • 15 Jun 2024 Results of pooled analysis of BE MOBILE 1 (NCT03928704) and 2 (NCT03928743) assessing the impact of BKZ , presented at the 25th Annual Congress of the European League Against Rheumatism
    • 12 Jun 2024 According to an UCB media release, company announced that the data of this trial is presented at the European Congress of Rheumatology, EULAR 2024, in Vienna, Austria, June 12 to 15.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top